Join to view full profile
5841 S Maryland AveChicago, IL 60637
Phone+1 888-824-0200
Fax+1 773-834-7374
Dr. Rampurwala is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Wisconsin Hospitals and ClinicsFellowship, Hematology and Medical Oncology, 2012 - 2015
University of ConnecticutResidency, Internal Medicine, 2009 - 2012
Government Medical College GujuratClass of 2007
Certifications & Licensure
IL State Medical License 2016 - 2029
WI State Medical License 2012 - 2017
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Inpatient 2014 Certified EHR Suite (with Beaker), Epic Systems Corporation, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Inpatient 2014 Certified EHR Suite, Epic Systems Corporation, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2016-2017
Clinical Trials
Publications & Presentations
PubMed
- A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: vaginal cancer sub cohort results.Young Kwang Chae, Josie Czeskleba, Sandip Pravin Patel, Alex Mentor, William Robinson
Journal of Gynecologic Oncology. 2026-09-01 - 3 citationsA randomized phase II trial of nab-paclitaxel with or without mifepristone for advanced triple-negative breast cancer.Nan Chen, Margarite Matossian, Poornima Saha, Murtuza Rampurwala, Salaija Kamaraju
Breast Cancer Research and Treatment. 2025-05-01 - 13 citationsSWOG/NCI Phase II Dual Anti-CTLA-4/PD-1 Blockade in Rare Tumors: Nonepithelial Ovarian Cancer.Young Kwang Chae, Megan Othus, Sandip Pravin Patel, Kelly J Wilkinson, Emily M Whitman-Purves
Clinical Cancer Research. 2024-12-16
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: